Generated October 2026 · Clinical Deep Dive 0 Comments On March 18, 2026, the FDA cleared icotrokinra (Icotyde), a once-daily oral peptide, for moderate-to-severe plaque psoriasis in patients as young as 12 years old and at least 40 kg who are candidates for systemic therapy or phototherapy…
Read More
